Vizsgálati helyszín
Northeast Research Institute
Fleming Island, Florida 32003, Egyesült ÁllamokMég nincs intézményhez kötve
- 13futó vizsgálat
- 11lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis19 vizsgálat
- 2. fázis4 vizsgálat
- 1. fázis1 vizsgálat
- Állapot
- Lezárult11 vizsgálat
- Fut, nem toboroz6 vizsgálat
- Toboroz5 vizsgálat
- Még nem toboroz2 vizsgálat
- Fő szponzor
- Novo Nordisk A/S22 vizsgálat
- Boehringer Ingelheim2 vizsgálat
Futó vizsgálatok
Még nem toboroz
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
NCT07931547· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Még nem toboroz
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Toboroz
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Toboroz
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
NCT07720271· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Toboroz
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587· 1. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Toboroz
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Fut, nem toboroz
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07533175· 3. fázis· Novo Nordisk A/S· Forrás
Fut, nem toboroz
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Fut, nem toboroz
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698· 2. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Fut, nem toboroz
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796· 3. fázis· Novo Nordisk A/S· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06131372· 2. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
NCT06326060· 2. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
NCT06269107· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
NCT05394519· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
NCT05486065· 2. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
NCT05352815· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
NCT05259033· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
NCT05013229· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
NCT03819153· 3. fázis· Novo Nordisk A/S· Forrás
Hibát jelzek